In a recent move, Michael E. Prevoznik, Senior Vice President and General Counsel of Quest Diagnostics Incorporated (NYSE:DGX), has sold a substantial number of shares in the company. The transaction, which took place on August 29, involved the sale of 32,551 shares at a weighted average price of $154.9727, bringing the total value of the sold shares to approximately $5,044,516.
This sale came on the same day Prevoznik exercised options to acquire the same number of shares at a price of $95.795 per share, amounting to a total of $3,118,223. Following these transactions, Prevoznik's direct holdings in the company decreased to 38,478 shares of common stock.
The sale prices for the shares ranged from $154.890 to $155.455, as detailed in a footnote to the filing. Prevoznik has agreed to provide full information regarding the specific number of shares sold at each price point upon request by the SEC staff, the issuer, or a security holder of the issuer.
Additionally, it was noted that Prevoznik has an indirect ownership of 5,592 shares through the company's tax-qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The options exercised by Prevoznik were part of a vesting schedule that began on February 21, 2018, with subsequent installments on February 21, 2019, and the final on February 21, 2020.
The executed transactions were reported in a Form 4 filing with the Securities and Exchange Commission, dated September 3, 2024.
In other recent news, Quest Diagnostics has seen significant developments. The company has completed the acquisition of LifeLabs, a leader in the Canadian diagnostics field, expected to generate approximately $710 million in annual revenues. Additionally, Quest Diagnostics is set to acquire select assets of the outreach laboratory services business from University Hospitals, Ohio, anticipated to finalize in the fourth quarter of 2024.
In terms of financials, Quest reported a 2.5% increase in total revenue for the second quarter of 2024, reaching $2.99 billion. The company's full-year 2024 financial guidance anticipates revenues between $9.5 billion and $9.58 billion, with reported EPS ranging from $7.57 to $7.77.
Mizuho maintained an Outperform rating on Quest and raised the price target to $160 from $155, following these developments. Evercore ISI also resumed its coverage on Quest Diagnostics, assigning an In Line rating and establishing a price target of $165.00.
Furthermore, Quest Diagnostics and BD (Becton, Dickinson and Company) have announced a global collaboration to develop flow cytometry-based companion diagnostics, aiming to enhance treatment selection for cancer patients and those with other diseases. These recent developments underscore Quest Diagnostics' commitment to growth and innovation in the healthcare diagnostics market.
InvestingPro Insights
Amid the news of Michael E. Prevoznik's share sale, Quest Diagnostics Incorporated (NYSE:DGX) continues to demonstrate a strong commitment to shareholder value. An InvestingPro Tip notes that management has been aggressively buying back shares, which can often signal confidence in the company's future prospects and a commitment to returning value to shareholders. Additionally, Quest Diagnostics has a notable track record of raising its dividend for 13 consecutive years, underscoring a reliable and growing income stream for investors.
From a financial standpoint, Quest Diagnostics presents a mixed picture. The company boasts a robust market capitalization of $17.43B, reflecting its significant presence in the diagnostics industry. However, it is currently trading at a high P/E ratio of 20.88, suggesting a premium valuation relative to near-term earnings growth. Despite this, the company has maintained dividend payments for an impressive 21 consecutive years, which is an important consideration for income-focused investors. On the growth front, revenue has seen a slight contraction of 1.5% over the last twelve months as of Q2 2024, indicating a need to monitor the company's top-line performance closely.
For investors seeking additional insights into Quest Diagnostics' financial health and stock performance, there are 9 more InvestingPro Tips available at https://www.investing.com/pro/DGX. These tips provide a deeper dive into the company's valuation, profitability, and stock price trends, helping investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.